Duravest, Inc.
OTC Bulletin Board : DUVT

Duravest, Inc.

February 01, 2006 07:59 ET

Duravest, Inc. and Estracure, Inc. Announce New Appointment to the Estracure Board

MONTREAL--(CCNMatthews - Feb 1, 2006) -

Estracure, Inc. - a subsidiary of Duravest, Inc. (OTC BB:DUVT, XETRA:DUV) has appointed Mr. Mason Drake as a member of the Board of Directors for Estracure replacing Mr. Petr Ondrousek. Mr. Drake is a partner at the New York law firm of Wollmuth Maher & Deutsch LLP where he practices corporate and transactional law with an emphasis on private company M&A, private equity investments and fund formation. His client base includes a number of public and private life sciences and healthcare companies. Mr. Drake is a graduate of Harvard College (A.B. magna cum laude) and the Northwestern University School of Law (J.D. cum laude). Dr. Ogan Gurel - CEO of Duravest and also a Director at Estracure - commented that: "Mr. Drake's extensive experience in corporate and transactional law, particularly as it relates to device and biotech companies will be an invaluable addition to the Estracure board. As one of the representatives of the Duravest controlling interest, he is the ideal individual for this position."

Dr. Jean Francois Tanguay, Chairman and Chief Scientific Officer of Estracure as well as a Director at Estracure added: "We are very pleased to have Mr. Drake join the Board of Directors of Estracure. We look forward to working with him, Dr. Gurel and the other Board members as we move Estracure ahead."

Background on Duravest, Inc.

Duravest (OTC BB:DUVT, XETRA:DUV) is a publicly traded holding company that initiates strategic investments in next-generation medical technology. Duravest identifies outstanding ideas in their preclinical stages and moves these to commercialization through key strategic partnerships. Duravest (through its subsidiary Estracure) is currently developing next-generation coronary stenting products based on proprietary estrogen-based technologies that minimize restenosis and potentially prevent progression of coronary lesions. The other Duravest subsidiary - Bio-Magnetic Therapy Systems, Inc. (BMTS) is a leading German-US medical technology firm dedicated to the safe, non-invasive treatment of osteoarthritis, osteoporosis and orthopedic injuries and associated pain management. Duravest is building the future of medicine now to create shareholder value and improve health.

Safe Harbor Forward Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals or assumptions of future events are not statements of historical fact and may be considered forward looking statements. They involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated.

Contact Information